Daewon Pharmaceutical and Celltrion Pharm Sign Co-Promotion Agreement for Three Antihypertensive Drugs

Accelerating Expansion in the Hypertension Market

Daewon Pharmaceutical announced on January 6 that it has signed a co-promotion agreement with Celltrion Pharm for three types of antihypertensive drugs.

(From left) Idalbi, Idaldipin, Idalbi-Clo product photos. Daewon Pharmaceutical

Under this agreement, Daewon Pharmaceutical and Celltrion Pharm will jointly promote and sell three antihypertensive products in Korea: Idalbi, Idalbiqlo, and Idaldipin.

Idalbi is an ARB (angiotensin II receptor blocker) antihypertensive drug characterized by an excellent T/P Ratio, which indicates how consistently its effects are maintained throughout the day. This results in low blood pressure variability. It demonstrates superior blood pressure-lowering efficacy compared to valsartan and olmesartan.

According to a clinical study comparing valsartan and olmesartan, the group administered 80 mg of Idalbi showed a greater reduction in blood pressure (-14.3 mmHg) than those given 320 mg of valsartan or 40 mg of olmesartan, other ARB agents. In addition, patients reached their target blood pressure quickly and effectively within 7.1 days of administration. The drug also has positive data for managing comorbidities, such as reducing microalbuminuria.

Notably, Idaldipin, newly introduced through this agreement, is an improved fixed-dose combination drug that combines azilsartan medoxomil, which has a strong blood pressure-lowering effect, with amlodipine, a leading calcium channel blocker (CCB).

According to the 2025 Fact Sheet from the Korean Society of Hypertension, about 60.3% of hypertensive patients take two or more medications. Among dual therapies, the combination of an ARB or ACE inhibitor (angiotensin-converting enzyme inhibitor) with a CCB accounts for the highest proportion at 71.4%. By adding a new combination product that meets high market demand to its lineup, Daewon Pharmaceutical expects to provide patients with a wider range of treatment options.

Daewon Pharmaceutical has already achieved significant results in the chronic disease treatment market. The lipid-lowering combination drug Tavarozet rapidly grew after its launch, ranking first in the generic market share in 2024. Tigfenon also holds the top position in the entire fenofibrate market, demonstrating the company’s strong sales and marketing capabilities in the field of cardiology.

A representative from Daewon Pharmaceutical stated, "By securing the rights to the Idalbi family, which has excellent efficacy and clinical evidence, our cardiovascular portfolio has been further strengthened. Based on our know-how in developing chronic disease treatments into blockbuster products, we will also solidify the market position of the Idalbi family."